ALVESCO

Compare ALVESCO  to:
Compare
Compare

Generic Name for ALVESCO

Ciclesonide 80mcg/inh, 160mcg/inh; metered dose aerosol.

Legal Classification:

Rx

Pharmacological Class for ALVESCO

Steroid.

Manufacturer of ALVESCO

Sepracor, Inc.

Indications for ALVESCO

Maintenance treatment of asthma as prophylactic therapy in patients ≥12 years of age.

Adult dose for ALVESCO

Previously on bronchodilators alone: initially 80mcg twice daily, max 160mcg twice daily. Previously on inhaled corticosteroids: initially 80mcg twice daily; max 320mcg twice daily. Previously on oral corticosteroids (see literature): 320mcg twice daily. Rinse mouth after use; avoid eyes.

Children's dosing for ALVESCO

Not recommended.

Contraindications for ALVESCO

Not for primary treatment of acute attack.

Precautions for ALVESCO

Infections. If exposed to chickenpox or measles, consider immuneglobulin prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Monitor for hypercorticism and HPA axis suppression (if occur reduce dose gradually). Monitor for growth suppression in children. Monitor for changes in vision, increased intraocular pressure, cataracts. Pregnancy (Cat.C). Nursing mothers.

Adverse Reactions for ALVESCO

Headache, nasopharyngitis, sinusitis, throat pain, upper respiratory infection, arthralgia, nasal congestion, back pain; rare: bronchospasm, immunosuppression, glaucoma, cataracts, oral candidiasis, decreased bone mineral density.

How is ALVESCO supplied?

Inhaler—6.1g (60 inh)

Related Disease:

Asthma~antiasthmatics

Related Resources

Orphan drug designation granted for aerosolized alpha1-proteinease inhibitor for alpha1-antitrypsin deficiency

February 08, 2010

Talecris Biotherapeutics was granted orphan drug designation by the FDA for the development of an aerosol formulation of alpha1-proteinease inhibitor to treat congenital alpha1-antitrypsin (AAT) deficiency.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Spiriva HandiHaler safety update

January 15, 2010

The FDA announced that data from a recent review of Spiriva HandiHaler (tiotropium dry powder for inhalation, from Boehringer Ingelheim) do not support an increased risk of stroke, heart attack, or death.

Spiriva HandiHaler approved for the reduction of COPD exacerbations

December 21, 2009

Spiriva HandiHaler (tiotropium powder for oral inhalation, from Boehringer Ingelheim and Pfizer) has been approved by the FDA for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Concentrated Prolastin-C approved for alpha1-antitrypsin (AAT) deficiency

October 19, 2009

The FDA has approved Prolastin-C (alpha1-proteinase inhibitor [human], from Talecris Biotherapeutics), a more concentrated formulation of Prolastin, for the treatment of alpha1-antitrypsin (AAT) deficiency.